Drug interaction – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:53 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Drug interaction – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Early vs. Delayed Ticagrelor with Cangrelor for Patients with STEMI Undergoing PCI https://clinicaltrials.eu/trial/study-on-early-vs-delayed-ticagrelor-with-cangrelor-for-patients-with-stemi-undergoing-pci/ Wed, 29 Apr 2026 15:00:40 +0000 https://clinicaltrials.eu/trial/study-on-early-vs-delayed-ticagrelor-with-cangrelor-for-patients-with-stemi-undergoing-pci/ This clinical trial is focused on patients experiencing an , a type of heart attack. The study is investigating the use of two medications: and . Cangrelor is given as an injection or infusion, while ticagrelor is taken as a tablet. The purpose of the study is to find out if giving ticagrelor earlier, at the start of the cangrelor infusion, is more effective than giving it later, towards the end of the cangrelor infusion, in reducing the risk of high platelet reactivity. High platelet reactivity means that the blood cells responsible for clotting are more active than usual, which can be risky for heart attack patients.

Participants in the study will receive either an early or delayed dose of ticagrelor while they are also receiving cangrelor. The study will compare the effects of these two timing strategies on the patients’ platelet activity. The researchers will also monitor for any major heart-related events, such as additional heart attacks or the need for further heart procedures, as well as any bleeding events, over a period of 30 days.

This study aims to improve the treatment approach for patients undergoing a procedure called , which is used to open blocked heart arteries during a STEMI. By understanding the best timing for administering ticagrelor, the study hopes to enhance patient outcomes and reduce complications associated with heart attacks.

]]>